Harrow Health (HROW) Set to Announce Quarterly Earnings on Thursday

Harrow Health (NASDAQ:HROW) is set to post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Harrow Health to post earnings of $0.12 per share for the quarter.

Harrow Health (NASDAQ:HROW) last posted its quarterly earnings results on Tuesday, March 12th. The company reported $0.77 EPS for the quarter, missing the consensus estimate of $0.84 by ($0.07). Harrow Health had a net margin of 35.35% and a return on equity of 177.27%. The company had revenue of $11.38 million for the quarter, compared to analysts’ expectations of $10.92 million. On average, analysts expect Harrow Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of Harrow Health stock traded up $0.01 on Tuesday, hitting $4.71. 2,122 shares of the company traded hands, compared to its average volume of 148,042. The company has a quick ratio of 2.61, a current ratio of 2.76 and a debt-to-equity ratio of 0.48. Harrow Health has a 12-month low of $1.99 and a 12-month high of $7.20. The stock has a market cap of $112.40 million, a P/E ratio of 7.72 and a beta of -0.02.

Several equities analysts have recently commented on the stock. TheStreet upgraded shares of Harrow Health from a “d-” rating to a “c” rating in a report on Wednesday, May 1st. Zacks Investment Research upgraded shares of Harrow Health from a “sell” rating to a “buy” rating and set a $6.00 price target on the stock in a report on Friday, March 15th. Finally, ValuEngine cut shares of Harrow Health from a “hold” rating to a “sell” rating in a report on Wednesday, March 27th.

In related news, Director Robert J. Kammer sold 10,000 shares of Harrow Health stock in a transaction on Monday, April 1st. The shares were sold at an average price of $4.77, for a total value of $47,700.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders sold 30,000 shares of company stock valued at $162,500. 12.43% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: This piece was posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.thelincolnianonline.com/2019/05/07/harrow-health-hrow-set-to-announce-quarterly-earnings-on-thursday.html.

About Harrow Health

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

Recommended Story: What strategies should day traders use to execute a trade?

Earnings History for Harrow Health (NASDAQ:HROW)

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.